Stock Short Interest Filing: What Will Happen to Neuralstem Incorporated (NASDAQ:CUR) Next? The Stock Has Increase in Shorts

November 30, 2016 - By kentuckypostne   ·   0 Comments

Stock Short Interest Filing: What Will Happen to Neuralstem Incorporated (NASDAQ:CUR) Next? The Stock Has Increase in Shorts

The stock of Neuralstem Incorporated (NASDAQ:CUR) registered an increase of 3.8% in short interest. CUR’s total short interest was 5.98M shares in November as published by FINRA. Its up 3.8% from 5.76M shares, reported previously. With 347,800 shares average volume, it will take short sellers 17 days to cover their CUR’s short positions. The short interest to Neuralstem Incorporated’s float is 5.77%. About 368,931 shares traded hands or 4.50% up from the average. Neuralstem, Inc. (NASDAQ:CUR) has declined 54.84% since April 27, 2016 and is downtrending. It has underperformed by 60.07% the S&P500.

Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $32.40 million. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. It currently has negative earnings. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insitutional Activity: The institutional sentiment decreased to 0.67 in Q2 2016. Its down 0.07, from 0.74 in 2016Q1. The ratio worsened, as 12 funds sold all Neuralstem, Inc. shares owned while 11 reduced positions. 8 funds bought stakes while 9 increased positions. They now own 20.82 million shares or 45.15% more from 14.35 million shares in 2016Q1.
Natl Planning has 0% invested in the company for 14,500 shares. Putnam Invs Ltd Liability Corporation has 0% invested in the company for 3.67 million shares. Bankshares Of America Corporation De has 3,258 shares for 0% of their US portfolio. The Ohio-based Fifth Third State Bank has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). The Virginia-based Davenport And Ltd Liability Com has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). Tci Wealth Inc has invested 0% of its portfolio in Neuralstem, Inc. (NASDAQ:CUR). Moreover, State Street Corp has 0% invested in Neuralstem, Inc. (NASDAQ:CUR) for 38,600 shares. Fcg Ltd Limited Liability Company reported 13,000 shares or 0% of all its holdings. Vanguard Gru Incorporated holds 0% or 3.38 million shares in its portfolio. Lpl Llc reported 91,816 shares or 0% of all its holdings. Blackrock Fund Advsrs holds 17,431 shares or 0% of its portfolio. Creative Planning has invested 0% of its portfolio in Neuralstem, Inc. (NASDAQ:CUR). Pnc Fincl Svcs Grp Inc Inc holds 0% of its portfolio in Neuralstem, Inc. (NASDAQ:CUR) for 31,000 shares. Hightower Advsrs Lc owns 93,282 shares or 0% of their US portfolio. Mackenzie Fincl Corp holds 0% or 196,200 shares in its portfolio.

CUR Company Profile

Neuralstem, Inc. (Neuralstem), incorporated on February 28, 2001, is a clinical-stage biopharmaceutical company. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions.

Another recent and important Neuralstem, Inc. (NASDAQ:CUR) news was published by Streetinsider.com which published an article titled: “Form 4 Neuralstem, Inc. For: Nov 25 Filed by: Daly Richard J” on November 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By kentuckypostne


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>